°ß°üÀý ÅëÁõÀ» µ¿¹ÝÇÑ µ¿°á°ß ȯÀÚ¿¡°Ô¼­ Buprenorphine transdermal patchÀÇ È¿°ú: ´Ü±â Ã߽à °á°ú
The Effectiveness of Buprenorphine Transdermal Patch on Patients with Shoulder Pain: Short-Term Follow-up Study

´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸÁö 2014³â 7±Ç 1È£ p.7 ~ p.12

È«ÁøÈ£(Hong Jin-Ho) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ Á¤Çü¿Ü°úÇб³½Ç
¹Ú¿ëº¹(Park Yong-Bok) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ Á¤Çü¿Ü°úÇб³½Ç
·ùÈ£¿µ(Ryu Ho-Young) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ Á¤Çü¿Ü°úÇб³½Ç
Àü»óÁØ(Jeon Sang-Jun) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ ÀçȰÀÇÇб³½Ç
¹Ú¿øÇÏ(Park Won-Ha) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ ÀçȰÀÇÇб³½Ç
À¯Àçö(Yoo Jae-Chul) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ Á¤Çü¿Ü°úÇб³½Ç

Abstract

¸ñÀû: °æÇÇ Buprenorphine Á¦Á¦´Â º¸Á¸Àû Ä¡·áÀÇ ÇÑ ¹æ¹ýÀ¸·Î ÀÌ¿ë ¹üÀ§¸¦ ³ÐÈ÷°í ÀÖÀ¸³ª Á¤Çü¿Ü°úÀÇ ¼¼ºÐÈ­µÈ ¿µ¿ª ¿¡¼­ÀÇ ÅëÁõ Á¶Àý È¿°ú¿¡ ´ëÇÑ ¿¬±¸´Â ¸¹Áö ¾Ê´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼­´Â °ß°üÀý ÅëÁõÀ» È£¼ÒÇÏ´Â µ¿°á±âÀÇ µ¿°á°ß ȯÀÚ¿¡ °Ô Åõ¿©ÇÑ °æÇÇ Buprenorphine Á¦Á¦ÀÇ ÅëÁõ Á¶Àý È¿°ú¿¡ ´ëÇØ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2013³â 3¿ù¿¡¼­ 9¿ù »çÀÌÀÇ ±â°£ µ¿¾È 5~6°³¿ù ÀÌ»ó °ß°üÀý ÅëÁõÀÌ Áö¼ÓµÇ°í ¿îµ¿¹üÀ§ÀÇ Á¦ÇÑÀÌ È®À뵂 ¾úÀ¸³ª ÀÚ±â°ø¸í ¿µ»ó °Ë»ç³ª ÃÊÀ½ÆÄ Áø´Ü °Ë»ç»ó °¡´ÉÇÑ ´Ù¸¥ º´¸®Àû ¼Ò°ßÀÌ ¹ß°ßµÇÁö ¾Ê¾Æ ÃÖÁ¾ÀûÀ¸·Î µ¿°á±â »óÅÂÀÇ µ¿°á°ßÀ¸·Î Áø´Ü ¹ÞÀº ÃÑ 127¸íÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ¸ðµç ȯÀÚµéÀº °üÀý¿Í-»ó¿Ï °üÀý ³» ½ºÅ×·ÎÀ̵å ÁÖ»ç¿ä¹ý À» 1ȸ ½ÃÇà ¹Þ¾Ò´Ù. ù ¿Ü·¡ ¹æ¹® ÀÌÈÄ 2~4ÁÖ ÈÄ ÀüÈ­¸¦ ÅëÇÑ ¼³¹®À» ½ÃÇàÇÏ¿´À¸¸ç Àüü 127¸íÀÇ ´ë»ó ȯÀÚ Áß 22¸í ÀÇ È¯ÀÚ°¡ ÀüÈ­ ¼³¹®À» °ÅºÎÇÏ¿© ÃÖÁ¾ 105¸íÀÇ È¯ÀÚ°¡ ´ë»óÀÌ µÇ¾úÀ¸¸ç ÀÌÁß °æ±¸ NSAID Á¦Á¦¿Í ÇÔ²² °æÇÇ Buprenorphine Á¦Á¦¸¦ ó¹æ ¹ÞÀº ½ÇÇ豺(BP group)Àº 51¸í, °æ±¸ NSAID Á¦Á¦ ¸¸À» ó¹æ ¹ÞÀº ´ëÁ¶±º(NP group)Àº 54¸íÀ̾ú´Ù. Ä¡·á È¿°úÀÇ Æò°¡¸¦ À§ÇÏ¿© ù ¿Ü·¡ ¹æ¹® ½Ã ¹× ÀüÈ­ ¼³¹® ½Ã ½Ã°¢Àû ÅëÁõ Á¡¼ö(PVAS), ½Ã°¢Àû ±â´É Á¡¼ö (FVAS), ¹Ì±¹ Á¤Çü¿Ü°ú °ßÁÖ°üÀý Á¡¼ö(ASES score)¸¦ ÃøÁ¤ÇÏ¿´´Ù.

°á°ú: Àü¹ÝÀûÀÎ ÅëÁõ ¹× ±â´É ÀÓ»ó Á¡¼ö¿¡¼­ ¾ç ±º µ¿ÀÏÇÏ°Ô Åõ¿© Àü º¸´Ù Åõ¿© ÈÄ¿¡ È£ÀüµÇ´Â Ãß¼¼¸¦ º¸¿´´Ù. °¢±ºÀÇ Æò °¡ Á¡¼öµéÀÇ Åõ¿© ÈÄ °á°ú´Â Åõ¿© Àü°ú ºñ±³ÇÏ¿© Åë°èÀûÀ¸·Î ÀÇ¹Ì ÀÖ°Ô È£ÀüµÇ¾ú´Ù(p<0.001). PVAS Á¡¼ö´Â BP group ¿¡¼­ 3.55, NP group ¿¡¼­ 2.87·Î BP group¿¡¼­ ¿ÀÈ÷·Á 0.68 ³ôÀº °ÍÀ¸·Î °üÂûµÇ¾úÀ¸³ª Åë°èÀûÀ¸·Î À¯ÀÇÇÏÁö´Â ¾Ê ¾Ò´Ù(p=0.088). Åõ¿© Àü ASES Á¡¼ö´Â µÎ ±º°£ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´ø ¹Ý¸é Åõ¿© ÈÄ Á¡¼ö´Â BP group¿¡¼­ 57.31, NP group¿¡¼­ 64.24·Î NP group¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p<0.05). ¹Ý¸é FVAS ´Â µÎ±º ¸ðµÎ È£ÀüµÇ´Â Ãß¼¼´Â º¸¿´À¸¸ç ¿ª ½Ã NP group¿¡¼­ ³ô¾ÒÀ¸¸ç Åõ¿© ÈÄ Á¡¼ö¿¡¼­ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸¿´´Ù(p<0.05).

°á·Ð: µ¿°á±âÀÇ µ¿°á°ß ȯÀÚ¿¡°Ô 1ȸ °üÀý ³» ½ºÅ×·ÎÀ̵å ÁÖ»çÄ¡·á ¹× °æ±¸ NSAID Á¦Á¦¿¡ Ãß°¡·Î Åõ¿©ÇÑ °æÇÇ Buprenorphine Á¦Á¦´Â ´Ü±â Ã߽ÿ¡¼­ Åõ¿©ÇÏÁö ¾ÊÀº °æ¿ìº¸´Ù ¿ì¿ùÇÑ ÅëÁõ ¹× ±â´ÉÀû ÀÓ»ó °á°ú¸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù.
Purpose:The effectiveness of transdermal buprenorphine patch on the patients with frozen state of frozen shoulder was evaluated.

Materials and Methods: Between March and September in 2013, 127 patients with pain and limited range of motion in shoulder joint over 6 months were included. Every patient was confirmed the diagnosis through MRI or ultrasonogram and each patient received intra-articular injection of steroid once. After 2~4 weeks, every patient was interviewed via telephone survey and finally 105 patients were included, 54 patients received only oral NSAIDs (NP group) while 51 patients received additional transdermal buprenorphine patch (BP group). Pain and functional visual analog scale (PVAS, FVAS), American Shoulder Elbow Society (ASES) score was checked.

Results: Generally, every outcome variables showed improvements in both groups (p<0.001). PVAS score after treatment showed superior result in NP group but it was not significant (p=0.088). In ASES score, NP group had superior result than BP group and it had significant difference. Similarly in FVAS, NP group showed superior result but the data before treatment was significantly different (p=0.028)

Conclusion: Transdermal buprenorphine patch didn¡¯t show superior treatment result in the patient with frozen state of frozen shoulder which was applied with oral NSAIDs after single intra-articular glenohumeral steroid injection in shortterm follow-up.

Ű¿öµå

Shoulder, Frozen shoulder, Adhesive capsulitis, Ultrasonogram, Conservative, Buprenorphine, Patch
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå